Non-small cell lung cancer
Conditions
Interventions
In vitro study:None
In vivo study:None
Sponsors
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. In vitro experiments (1) Aged 18 to 75 years; (2) NSCLC diagnosed by histopathology and expressing any rare EGFR mutation such as 20 insertion, G719X, L861Q, S768I or L747S; (3) Malignant pleural effusion exists, and pleural effusion treatment is required; (4) The subjects themselves participated voluntarily and signed the informed consent in writing. 2. In vivo experiments (1) Aged 18 to 75 years; (2) NSCLC was diagnosed by histopathology, and there were rare mutations in EGFR exons 18-21 detected by second-generation high-throughput sequencing; (3) Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2, and no deterioration in the previous 2 weeks, with a minimum expected survival of 12 weeks; (4) The patient has at least one tumor lesion that can be accurately measured at baseline, and the longest diameter at baseline is >=10 mm (if it is a lymph node, the short diameter is required to be >=15 mm). The measurement method chosen is suitable for accurate repeat measurements and can be computed tomography (CT) or magnetic resonance scan (MRI). If there is only one measurable lesion, it can be accepted as a target lesion, and a baseline evaluation of tumor lesions should be performed at least 14 days after diagnostic biopsy; (5) are receiving or planning to receive almetinib treatment; (6) The subjects themselves participated voluntarily and signed the informed consent in writing.
Exclusion criteria
Exclusion criteria: 1. Those who are allergic to Ametinib mesylate tablets and/or its excipients; 2. Pregnant or lactating women; 3. There are contraindications to Ametinib; 4. The doctor thinks it is not suitable for inclusion.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| ty of almonertinib to inhibit the growth of Plasmacytoid Dendritic Cells;Mechanism of almonertinib; | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes of tumor volume;Progression free survival;Overall survival;Safety; | — |
Countries
China
Contacts
Public ContactZhang Yu
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Outcome results
None listed